# WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck

> **NCT02508246** · PHASE1 · COMPLETED · sponsor: **University of Washington** · enrollment: 12 (actual)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** Docetaxel
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **PROCEDURE:** Therapeutic Conventional Surgery
- **DRUG:** WEE1 Inhibitor AZD1775

## Key facts

- **NCT ID:** NCT02508246
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-22
- **Primary completion:** 2018-04-26
- **Final completion:** 2018-04-26
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2019-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02508246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02508246, "WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02508246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*